Influence of Echinacea purpurea intake during pregnancy on fetal growth and tissue angiogenic activity.

The process of angiogenesis and control of blood vessels sprouting are fundamental to human health, as they play key roles in many physiological and pathological conditions. Intake of different pharmaceuticals with antiangiogenic activity by pregnant women may lead to severe developmental disturbances as it was described in case of thalidomide. It may also cause immunomodulatory effects as it was shown for antibiotics, theobromine, caffeic acid or catechins on the pregnant mice model. At present, Echinacea purpurea-based phytoceuticals are among the most popular herbals in the marketplace. Many compounds of Echinacea extracts (polysaccharides, alkamides, polyphenols, glycoproteins) exert immunomodulatory, anti-oxidative and anti-inflammatory activity. Echinacea is one of the most powerful and effective remedies against many kinds of bacterial and viral infections. In previous studies we shown significant inhibitory effect of the Echinacea purpurea based remedy on tumour angiogenic activity using cutaneous angiogenesis test, and an inhibitory effect on L-1 sarcoma growth was observed . The aim of the present study was to establish whether pharmaceuticals containing alcoholic extracts of Echinacea purpurea given to pregnant mice influence angiogenic activity and tissue VEGF and bFGF production of their fetuses. We showed that angiogenic activity of tissue homogenates was increased in Esberitox group and diminished in case of Immunal forte as compared to standard diet group. In case of Echinapur group we did not find significant differences in angiogenic activity. VEGF and bFGF concentration were lower in all groups compared to the control. In the case of Echinapur and Esberitox number of fetuses in one litter were slightly lower as compared to control group, but the difference is on the border of statistical significance. In conclusion, there is some possibility that pharmaceuticals containing Echinacea purpurea might influence fetal development in human also, because they may interfere with embrional angiogenesis , and should not be recommended for pregnant women.

[1]  Evan R. Ball,et al.  Angiogenesis in implantation , 2007, Journal of Assisted Reproduction and Genetics.

[2]  A. Koch,et al.  Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. , 2007, Arthritis and rheumatism.

[3]  Paola Viganò,et al.  The role of macrophage migration inhibitory factor in maintaining the immune privilege at the fetal–maternal interface , 2007, Seminars in Immunopathology.

[4]  T. Johns,et al.  Dietary Echinacea purpurea during Murine Pregnancy: Effect on Maternal Hemopoiesis and Fetal Growth , 2006, Neonatology.

[5]  Janet Rossant,et al.  Endothelial cells and VEGF in vascular development , 2005, Nature.

[6]  Anna Lipińska,et al.  Increased interleukin-18 content and angiogenic activity of sera from diabetic (Type 2) patients with background retinopathy. , 2005, Journal of diabetes and its complications.

[7]  D. Roth-Maier,et al.  Efficiency of Echinacea purpurea on performance and immune status in pigs. , 2005, Journal of animal physiology and animal nutrition.

[8]  E. Ernst,et al.  The Safety of Herbal Medicinal Products Derived from Echinacea Species , 2005, Drug safety.

[9]  Sandra C. Miller,et al.  Enhancement of natural killer cells and increased survival of aging mice fed daily Echinacea root extract from youth , 2005, Biogerontology.

[10]  E. Skopińska-Różewska,et al.  The effect of complex herbal remedy on the angiogenic activity of L-1 sarcoma cells, L-1 sarcoma tumour growth, and on the bacterial infection in mice , 2004 .

[11]  H. Nordeng,et al.  Use of herbal drugs in pregnancy: a survey among 400 Norwegian women , 2004, Pharmacoepidemiology and drug safety.

[12]  P. Wei,et al.  VEGF, bFGF and their receptors at the fetal-maternal interface of the rhesus monkey. , 2004, Placenta.

[13]  K. Münstedt,et al.  Angiogenesis and vasculogenesis in pregnancy. , 2003, European journal of obstetrics, gynecology, and reproductive biology.

[14]  H. Wagner,et al.  Polysaccharides isolated from Echinacea purpurea herba cell cultures to counteract undesired effects of chemotherapy—a pilot study , 2002, Phytotherapy research : PTR.

[15]  Jan V Slama,et al.  Alkylamides of Echinacea purpurea stimulate alveolar macrophage function in normal rats. , 2002, International immunopharmacology.

[16]  M. Nair,et al.  Bioactivity of alkamides isolated from Echinacea purpurea (L.) Moench. , 2002, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[17]  G. Koren,et al.  Can herbal products be used safely during pregnancy? Focus on echinacea. , 2001, Canadian family physician Medecin de famille canadien.

[18]  E. Skopińska-Różewska,et al.  Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells. , 2000, Oncology reports.

[19]  B. G. Hughes,et al.  Echinacea-induced cytokine production by human macrophages. , 1997, International journal of immunopharmacology.

[20]  J. Tilles,et al.  In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. , 1997, Immunopharmacology.

[21]  G. Aldini,et al.  Echinacoside and Caffeoyl Conjugates Protect Collagen from Free Radical-Induced Degradation: A Potential Use of Echinacea Extracts in the Prevention of Skin Photodamage , 1995, Planta medica.

[22]  A. Kiderlen,et al.  Application of purified polysaccharides from cell cultures of the plant Echinacea purpurea to mice mediates protection against systemic infections with Listeria monocytogenes and Candida albicans. , 1991, International journal of immunopharmacology.

[23]  G. Gifford,et al.  Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea. , 1989, Journal of the National Cancer Institute.